Improved protocol to expand patients cells ex vivo for cancer immunotherapy
2014
Uppsala University, Uppsala, Sweden
Adoptive T-cell therapy of cancer is a treatment strategy where T cells are isolated, activated, in some cases engineered, and expanded ex vivo before being reinfused to the patient. Unfortunately, T cells expanded using the commonly used “rapid expansion protocol” (REP) are sensitive to the harsh tumor microenvironment and are often shortlived after reinfusion. In the present study, the researchers demonstrate that an alternative "allosensitized allogeneic lymphocytes expansion protocol" (AEP) allow for obtaining T cells with better survival and cytotoxic efficacy under oxidative stress and immunosuppressive environment, as well as a superior proliferative response during tumor cell killing compared to the REP protocol. These results show a robust ex vivo method to expand T cells with improved quality for adoptive cancer immunotherapy. T cells were isolated from donors' peripheral blood and expanded ex vivo. Assays for cytotoxicity were done in vitro using established human cell lines.
Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors
Magnus Essand
Added on: 07-28-2021
[1] https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(16)30075-4?[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
